Cohort demographics, clinical characteristics, and response to CD19-CAR
| Patient . | Response categorization . | Relapse status at time of CD19-CAR . | Prior HCT . | Prior blinatumomab . | Pre-CAR leukemic burden (n %) . | Known cytogenetics . | Pre-CAR surface CD19 . | Post CD19-CAR surface CD19 . | Best response and duration . |
|---|---|---|---|---|---|---|---|---|---|
| S09 | PNR | Second relapse | Yes (1) | No | 92 | iAMP21 | Positive | Positive | PD |
| S27 | PNR | First relapse | No | No | 97 | iAMP21 | Positive | Positive | PD |
| S31 | PNR | second relapse | No | No | 80 | t(5;14) | Positive | Positive | Initial MRD– CR; CD19+ B-ALL present within 3 wk |
| S37 | PNR | Third relapse | Yes (1) | No | 59 | ETV6-RUNX1 | Positive | Positive | Initial MRD– CR; CD19+ B-ALL present within 3 wk |
| S46 | PNR | 2nd Relapse | Yes (1) | Yes | 94.5 | 46, XY, 22 PSTL+ | Positive | Positive | PD |
| S1023 | PNR | 3rd Relapse | No | No | 100 | 46, XY, t(9:12)(p24;p13)/46, idem, del(1)(q41)/47, idem, +8 IKZF deletion | Positive | Positive | PD |
| S1057 | PNR | 1st Relapse | No | No | 30 | 67-68 (3n), -X, i(X)(q10), +1, i(1)(q10), −3, −4, del(6)(q13q23), +6, −7, +8, −10, −12, −13, +14, −16, −17, −17, +20, +22, +22/46, XX(20) | Positive | Positive | PD |
| S01 | PS | 2nd Relapse | Yes (1) | No | 59 | Ph-like | Positive | MRD– | MRD– CR; ongoing >7 y |
| S07 | PS | 2nd Relapse | Yes (1) | Yes | 77 | KMT2A-rearrangement | Positive | MRD– | MRD– CR; ongoing >6 y |
| S19 | PS | 2nd Relapse | Yes (1) | No | 75.8 | 55, XX | Positive | MRD– | MRD– CR; CD19 negative recurrence at 19 mo |
| S36 | PS | 2nd Relapse | No | No | 85 | 46, XX with inv | Positive | MRD– | MRD– CR; ongoing >5 y |
| S43 | PS | 4th Relapse | Yes (2) | No | 23 | Ph+ | Positive | MRD– | MRD– CR; CD19+ recurrence at 11 mo |
| S53 | PS | 3rd Relapse | Yes (1) | Yes | 1.9 | Trisomy 1, 4, 9, 10, 12, 17, 21 | Positive | MRD– | MRD– CR; ongoing >5 y |
| S58 | PS | 1st Relapse | Yes (1) | No | 4.4 | Tetrasomy 21, Trisomy 8 | Positive | MRD– | MRD– CR; ongoing >5 y |
| Patient . | Response categorization . | Relapse status at time of CD19-CAR . | Prior HCT . | Prior blinatumomab . | Pre-CAR leukemic burden (n %) . | Known cytogenetics . | Pre-CAR surface CD19 . | Post CD19-CAR surface CD19 . | Best response and duration . |
|---|---|---|---|---|---|---|---|---|---|
| S09 | PNR | Second relapse | Yes (1) | No | 92 | iAMP21 | Positive | Positive | PD |
| S27 | PNR | First relapse | No | No | 97 | iAMP21 | Positive | Positive | PD |
| S31 | PNR | second relapse | No | No | 80 | t(5;14) | Positive | Positive | Initial MRD– CR; CD19+ B-ALL present within 3 wk |
| S37 | PNR | Third relapse | Yes (1) | No | 59 | ETV6-RUNX1 | Positive | Positive | Initial MRD– CR; CD19+ B-ALL present within 3 wk |
| S46 | PNR | 2nd Relapse | Yes (1) | Yes | 94.5 | 46, XY, 22 PSTL+ | Positive | Positive | PD |
| S1023 | PNR | 3rd Relapse | No | No | 100 | 46, XY, t(9:12)(p24;p13)/46, idem, del(1)(q41)/47, idem, +8 IKZF deletion | Positive | Positive | PD |
| S1057 | PNR | 1st Relapse | No | No | 30 | 67-68 (3n), -X, i(X)(q10), +1, i(1)(q10), −3, −4, del(6)(q13q23), +6, −7, +8, −10, −12, −13, +14, −16, −17, −17, +20, +22, +22/46, XX(20) | Positive | Positive | PD |
| S01 | PS | 2nd Relapse | Yes (1) | No | 59 | Ph-like | Positive | MRD– | MRD– CR; ongoing >7 y |
| S07 | PS | 2nd Relapse | Yes (1) | Yes | 77 | KMT2A-rearrangement | Positive | MRD– | MRD– CR; ongoing >6 y |
| S19 | PS | 2nd Relapse | Yes (1) | No | 75.8 | 55, XX | Positive | MRD– | MRD– CR; CD19 negative recurrence at 19 mo |
| S36 | PS | 2nd Relapse | No | No | 85 | 46, XX with inv | Positive | MRD– | MRD– CR; ongoing >5 y |
| S43 | PS | 4th Relapse | Yes (2) | No | 23 | Ph+ | Positive | MRD– | MRD– CR; CD19+ recurrence at 11 mo |
| S53 | PS | 3rd Relapse | Yes (1) | Yes | 1.9 | Trisomy 1, 4, 9, 10, 12, 17, 21 | Positive | MRD– | MRD– CR; ongoing >5 y |
| S58 | PS | 1st Relapse | Yes (1) | No | 4.4 | Tetrasomy 21, Trisomy 8 | Positive | MRD– | MRD– CR; ongoing >5 y |
AMP, amplification; inv, inversion; Ph, Philadelphia chromosome (BCR-ABL1); PD, progressive disease; PSTL, PSTL polymorphism; XX: duplication of X chromosome.